GlassScriptPhysician profile
Robert Noyes Etheridge
NPI 1588007603
$999.94
in general payments reported to CMS, 2019-2025
19 companies · $253 in 2025
The $253 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30.67 · 2020: $29.77 · 2021: $12.40 · 2022: $64.26 · 2023: $197 · 2024: $413 · 2025: $253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $863.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $862.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $144.31 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $116.08 | 2023-2025 | Synjardy, Jardiance, Tradjenta |
| Novo Nordisk INC | $86.93 | 2020-2024 | Ozempic, Rybelsus |
| Dexcom, INC. | $73.65 | 2023-2024 | Dexcom G6 Transmitter |
| Abbvie INC. | $68.45 | 2019-2024 | |
| Abbott Laboratories | $67.96 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Insulet Corporation | $63.14 | 2024 | Omnipod |
| Pfizer INC. | $57.78 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $53.35 | 2024-2025 | |
| Gilead Sciences, INC. | $42.87 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $39.85 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $38.15 | 2023-2024 | Dificid, Gardasil 9, Gardasil |
| Novartis Pharmaceuticals Corporation | $34.60 | 2022 | |
| Hologic Sales and Service, LLC | $26.37 | 2024 | Aptima |
| Corcept Therapeutics | $23.61 | 2025 | Korlym |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $20.83 | 2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $15.12 | 2024 | Arexvy, Trelegy Ellipta |
| Indivior INC. | $14.63 | 2024 | Sublocade |
| Tetraphase Pharmaceuticals, INC. | $12.26 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Etheridge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.